Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients

NCT06287749 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT06287749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06287749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients
Lead sponsor
University Hospital, Montpellier
Phase
Observational
Overall status
Recruiting
Start date
March 1, 2024
Completion date
October 31, 2028
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ctdna, liquid biopsy, minimal residual disease, pancreatic cancer resectable, pancreatic ductal adenocarcinoma